|Apr. 1988||LTT Research Institute was established for the purpose of support of research and development of DDS-related technologies.|
|Jun. 1988||Limethason®, a DDS product developed by LTT, was marketed by Mitsubishi Tanabe Pharma Corp. (former Green Cross Corp.).|
|July. 1988||Haloart®, a DDS product developed by LTT, was marketed by Taiho Pharmaceutical Co., Ltd.|
|Oct. 1988||Palux Injection®, a DDS product developed by LTT, was marketed by Taisho Pharmaceutical Co., Ltd.|
|Nov. 1988||Liple Injection®, a DDS product developed by LTT, was marketed by Mitsubishi Tanalo Pharma Corp. A contract research agreement was concluded with St. Marianna University.|
|Oct. 1990||Institute of Medical Science St. Marianna Univ. School of Medicine was established.|
|Jun. 1992||Ropion Injection®, a DDS product developed by LTT, was marketed by Kaken Pharmaceutical Co., Ltd.|
|Mar. 1995||Beijing Tide Pharmaceutical Co., Ltd. was established jointly with China-Japan Friendship Hospital, Beijing, China. Manufacturing of Lipo-PGE1 product was started in China with the technical support from Taisho Pharmaceutical Co., Ltd.|
|Sep. 1998||Farnezone and Farnerate were marketed by Taiho Pharmaceutical Co., Ltd. and Dainippon Sumitomo Pharmaceutical Co., Ltd., respectively.|
|Nov. 2001||The head office was moved to Atago, Minato-ku, Tokyo.|
|Jan. 2003||LTT Bio-Pharma was founded by corporate separation from LTT Research Institute to transfer the pharmaceutical business.|
|Nov. 2004||LTT Bio-Pharma was listed on TSE Mothers.|
|Jun. 2005||Perfect Lift AA, a DDS product developed by LTT, was marketed by Rohto Pharmaceutical Co., Ltd.|
|Nov. 2006||An Early Phase Ⅱ clinical study of PC-SOD has been completed in Japan.
This study showed that PC-SOD was effective for ulcerative colitis.
|May. 2008||Dr. Yutaka Mizushima passed away.|
|Jun. 2008||An Early Phase Ⅱ clinical study of PC-SOD has been completed in Japan.
This study showed that PC-SOD was effective for idiopathic intersttial pheumonia.
|Feb. 2009||The head office was moved to Kaigan,Minato-ku,Tokyo.|
|Feb. 2009||LTT Bio Pharma Transferred Stocks of Sole Corporation.
Deviate from consolidated companies.
|Apr. 2009||Capital and business alliance agreement was concluded with Beijing Tide Pharmaceutical Co., Ltd.|
|Aug. 2009||PC-SOD NE was adopted at NEDO(Government-subsidized projects)|
|Sep. 2009||LTT-Bio Pharma had an exclusive license agreement (AS-013) with Beijing Tide Pharma at China.|
|Jan. 2010||LTT Bio Pharma made a collaborative research agreement(Stealth Type Nano-Particle Formulation) with Asahi Kasei Pharma corporation.
It started basic research.
|Jul. 2010||Stealth Type Nano-Particle Formulation was adopted at NEDO(Government- subsidized projects)|
|Sep. 2010||PhaseI study of PC-SOD NE was started.|
|Nov. 2010||LTT-Bio Pharma had an exclusive license agreement with Beijing Tide Pharma on Stealth Type Nano-Particle Formulation.|
|Dec. 2010||We started Repeated-dose study of PC-SOD NE(PhaseI study) on healthy volunteer.|
|Jul. 2011||LTT-Bio Pharma had an exclusive license agreement with Chon Kun Dang Pharma Corp.(CKD) on PC-SOD NE.|
|Aug. 2011||LTT Bio Pharma’s stocks was delisting. (Aug 9. 2011)|
|Feb. 2012||Reduced the capital in a hundred million yen. (Feb. 10. 2012)
Investigational New Drug (IND) application of Phase II clinical study for PC-SOD NE.
|Jul. 2012||Phase II global clinical trial (Japan and Korea) of PC-SOD NE was started.|
|Sep. 2014||Phase II global clinical trial of PC-SOD NE has been completed.|
|Oct. 2015||LT-4004 license contract was concluded with Ajinomoto Pharma Co., Ltd.|
|Apr. 2016||Established laboratory in St.Marianna University.|
|May. 2016||Phase II clinical trial of LT-4002 has been started.|